Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome (original) (raw)

Nature Neuroscience volume 10, pages 411–413 (2007)Cite this article

Abstract

Ts65Dn mice, a model for Down syndrome, have excessive inhibition in the dentate gyrus, a condition that could compromise synaptic plasticity and mnemonic processing. We show that chronic systemic treatment of these mice with GABAA antagonists at non-epileptic doses causes a persistent post-drug recovery of cognition and long-term potentiation. These results suggest that over-inhibition contributes to intellectual disabilities associated with Down syndrome and that GABAA antagonists may be useful therapeutic agents for this disorder.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Seregaza, Z., Roubertoux, P.L., Jamon, M. & Soumireu-Mourat, B. Behav. Genet. 36, 387–404 (2006).
    Article Google Scholar
  2. Holtzman, D.M. et al. Proc. Natl. Acad. Sci. USA 93, 13333–13338 (1996).
    Article CAS Google Scholar
  3. Kurt, M.A., Davies, D.C., Kidd, M., Dierssen, M. & Florez, J. Brain Res. 858, 191–197 (2000).
    Article CAS Google Scholar
  4. Belichenko, P.V. et al. J. Comp. Neurol. 480, 281–298 (2004).
    Article Google Scholar
  5. Hanson, J.E., Blank, M., Valenzuela, R.A., Garner, C.C. & Madison, D.V. J. Physiol. (Lond.) (in the press).
  6. Kleschevnikov, A.M. et al. J. Neurosci. 24, 8153–8160 (2004).
    Article CAS Google Scholar
  7. Costa, A.C.S. & Grybko, M.J. Neurosci. Lett. 382, 317–322 (2005).
    Article CAS Google Scholar
  8. Nadel, L. Genes Brain Behav. 2, 156–166 (2003).
    Article CAS Google Scholar
  9. McGaugh, J.L. Science 153, 1351–1358 (1966).
    Article CAS Google Scholar
  10. Ivic, L. et al. J. Biol. Chem. 278, 49279–49285 (2003).
    Article CAS Google Scholar
  11. Levy, S. J. Am. Med. Assoc. 153, 1260–1265 (1953).
    Article CAS Google Scholar
  12. Landfield, P.W., Baskin, R.K. & Pitler, T.A. Science 214, 581–584 (1981).
    Article CAS Google Scholar
  13. Gerlai, R. Behav. Brain Res. 95, 91–101 (1998).
    Article CAS Google Scholar
  14. Whitlock, J.R., Heynen, A.J., Shuler, M.G. & Bear, M.F. Science 313, 1093–1097 (2006).
    Article CAS Google Scholar
  15. Pastalkova, E. et al. Science 313, 1141–1144 (2006).
    Article CAS Google Scholar

Download references

Acknowledgements

We thank the Down Syndrome Research and Treatment Foundation (DSRTF), the Hillblom Foundation, the US National Science Foundation (NSF), the US National Institute of Health (NIH), Jax West Laboratories, the Stanford Down Syndrome Center and W.C. Mobley for their support.

Author information

Authors and Affiliations

  1. Department of Psychiatry and Behavioral Sciences, Nancy Pritzker Laboratory, Stanford University, Palo Alto, 94304-5485, California, USA
    Fabian Fernandez, Wade Morishita, Elizabeth Zuniga, James Nguyen, Martina Blank, Robert C Malenka & Craig C Garner

Authors

  1. Fabian Fernandez
    You can also search for this author inPubMed Google Scholar
  2. Wade Morishita
    You can also search for this author inPubMed Google Scholar
  3. Elizabeth Zuniga
    You can also search for this author inPubMed Google Scholar
  4. James Nguyen
    You can also search for this author inPubMed Google Scholar
  5. Martina Blank
    You can also search for this author inPubMed Google Scholar
  6. Robert C Malenka
    You can also search for this author inPubMed Google Scholar
  7. Craig C Garner
    You can also search for this author inPubMed Google Scholar

Contributions

F.F. designed and executed all behavioral experiments with the assistance of E.Z. and J.N. W.M. performed all of the electrophysiology experiments. M.B. provided technical expertise in breeding and genotyping. F.F., C.C.G., W.M. and R.C.M. wrote and edited the manuscript.

Corresponding author

Correspondence toCraig C Garner.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Fig. 1

Ts65Dn mice exhibit declarative memory problems, but intact procedural learning. (PDF 101 kb)

Supplementary Fig. 2

Chronic but not acute administration of picrotoxin (PTX) normalizes Ts65Dn performance in the novel object recognition task. (PDF 94 kb)

Supplementary Table 1

Tabulated discrimination indices (DI's) in the novel object recognition task. (PDF 148 kb)

Supplementary Table 2

Picrotoxin (PTX), bilobalide (BB) and pentylenetetrazole (PTZ) do not affect exploration times in the novel object recognition task. (PDF 148 kb)

Supplementary Table 3

Tabulated alternation percentages (%) in the spontaneous alternation task. (PDF 154 kb)

Supplementary Table 4

Pentylenetetrazole (PTZ) does not affect arm entries in the spontaneous alternation task. (PDF 147 kb)

Supplementary Discussion

Potential utility of non-competitive GABAA receptor antagonists for the treatment of cognitive impairment in Down syndrome. (PDF 97 kb)

Supplementary Methods (PDF 104 kb)

Rights and permissions

About this article

Cite this article

Fernandez, F., Morishita, W., Zuniga, E. et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome.Nat Neurosci 10, 411–413 (2007). https://doi.org/10.1038/nn1860

Download citation

This article is cited by